ANAVEX 2-73/donepezil

Drug Profile

ANAVEX 2-73/donepezil

Alternative Names: ANAVEX 2-73/DPZ; ANAVEX PLUS; Donepezil/ANAVEX 2-73

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anavex Life Sciences
  • Class Antidementias; Dimethylamines; Furans; Indans; Neuroprotectants; Nootropics; Piperidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Calcium channel antagonists; Muscarinic M2 receptor antagonists; Muscarinic M3 receptor antagonists; NMDA receptor antagonists; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 05 Sep 2017 Anavex Life Sciences has patent protection for ANAVEX 2-73/donepezil in USA
  • 15 Mar 2017 Phase-II development is ongoing in Australia
  • 01 Jan 2017 Anavex Life Sciences completes a phase IIa trial for Alzheimer's disease in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top